Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

This study introduced a novel scarless healing material called pgPE, made from a porous UHMWPE nanomembrane, and found that it promotes complete skin reconstruction and hair follicle regeneration by alleviating hypoxia and modulating immune responses to foster scar-free wound healing.

This study found that bioconjugating 16-methylheptadecanoic acid (16-MHA) to damaged hair can mimic the protective properties of 18-methyleicosanoic acid (18-MEA), restoring the hair's structural integrity and moisture homeostasis, even after washing.

In this study, imaging techniques showed that nanostructured lipid carrier formulations distributed ascorbic acid more effectively across skin layers compared to conventional cream formulations, suggesting a better method for skin permeation.

This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

JAK inhibitors are generally safe for treating alopecia areata.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.

In this reported case, a 30-year-old man with a long history of alopecia universalis experienced limited regrowth of eyebrows and eyelashes after six months of deuruxolitinib, despite unchanged scalp hair, suggesting site-specific potential for hair regrowth in challenging cases.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

This study observed that patients with acute alopecia areata treated with Janus kinase inhibitors achieved a higher rate of complete hair regrowth by week 24 compared to those with non-acute disease, highlighting the benefits of early intervention.

This case report documents an unusual instance of follicular vitiligo in a young woman, characterized by selective hair depigmentation on the forearms, distinctive dermoscopic and Wood's lamp findings, and histological evidence suggesting functional impairment rather than complete loss of follicular melanocytes.

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This study found that low-dose oral minoxidil increased terminal hair density in patients with androgenetic alopecia, providing an alternative dosage comparable to the topical 5% solution.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

This study observed that JAK inhibitors were effective and safe for treating alopecia totalis and universalis, with improved response rates seen most with ritlecitinib and tofacitinib by week 24.

This research found that kaempferol, a flavonoid from hair growth-promoting plants, significantly enhanced human dermal papilla cell proliferation and inhibited specific signaling pathways, outperforming minoxidil, with topical application in mice promoting hair growth and thickness, indicating potential as a natural hair loss treatment.

This source describes a case where a patient with Crohn's disease experienced remission of alopecia universalis after a colectomy, suggesting that addressing the intestinal inflammatory source might influence autoimmune manifestations like hair loss.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

A thorough assessment and combined treatment are crucial for managing complex alopecia, especially in patients with skin of color.

This study examined Chinese adult patients' discussions on social media about JAK inhibitors for alopecia areata, highlighting significant interest in these treatments but also concerns about efficacy, relapse, side effects, and the emotional impact of the condition.

This study assessed the effectiveness of JAK inhibitors in Jordanian patients with alopecia areata, finding that while both tofacitinib and baricitinib improved SALT scores, baricitinib showed greater improvement and a trend towards better hair regrowth, particularly with longer treatment durations.

This study investigated alopecia areata in a mouse model, finding that tofacitinib may inhibit disease progression by modulating linoleic acid metabolism and magnesium pathways, particularly affecting CD8+ T cell infiltration in hair follicles, offering insights for potential treatments.